Drug Profile
Research programme: gastrointestinal disorder therapeutics - Nxera Pharma/Jitsubo
Alternative Names: JIT 8012Latest Information Update: 02 Apr 2024
Price :
$50
*
At a glance
- Originator Heptares Therapeutics; Jitsubo
- Developer Jitsubo; Nxera Pharma
- Class Peptides
- Mechanism of Action G protein-coupled receptor modulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Gastrointestinal disorders
Most Recent Events
- 31 Mar 2024 Sosei Heptares is now called Nxera Pharma
- 28 Dec 2020 No recent reports of development identified for research development in Gastrointestinal-disorders in Japan (Parenteral)
- 28 Dec 2020 No recent reports of development identified for research development in Gastrointestinal-disorders in United Kingdom (Parenteral)